Search research articles
Contact Us
Filters
Showing results (11-20 of 73) with videos related to
Page
of 8
Sort By:
Expert Opinion on Drug Safety
|
February 27, 2023
The safety and efficacy of interleukin 11 for radiation injury
Vijay K Singh, Thomas M Seed
Life Sciences in Space Research
|
November 6, 2022
Armed Forces Radiobiology Research Institute/Uniformed Services University of the Health Sciences perspective on space radiation countermeasure discovery
Vijay K Singh, Thomas M Seed
Expert Opinion on Pharmacotherapy
|
January 14, 2020
Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems
Vijay K Singh, Thomas M Seed
Expert Opinion on Drug Discovery
|
August 30, 2021
How necessary are animal models for modern drug discovery?
Vijay K Singh, Thomas M Seed
Expert Opinion on Pharmacotherapy
|
August 17, 2024
New pharmaceutical-based strategies that foster the development and promulgation of globally effective medical countermeasures for radiation exposure injuries
Vijay K Singh, Thomas M Seed
Drugs of Today (Barcelona, Spain : 1998)
|
March 11, 2022
An update on romiplostim for treatment of acute radiation syndrome
Vijay K Singh, Thomas M Seed
Expert Opinion on Drug Discovery
|
November 6, 2025
Cutting-edge animal models for radiation combined injury drug development
Vijay K Singh, Thomas M Seed
Frontiers in Pharmacology
|
May 27, 2021
Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure
Vijay K Singh, Thomas M Seed
Journal of Applied Toxicology : JAT
|
November 25, 2003
Genistein treatment protects mice from ionizing radiation injury
Michael R Landauer, Venkataraman Srinivasan, Thomas M Seed
International Journal of Radiation Biology
|
June 29, 2017
A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status
Vijay K Singh, Melissa Garcia, Thomas M Seed
Page
of 8
Search research articles
Search
Showing results (11-20 of 73) with videos related to
Sort By:
Page
of 8
Expert Opinion on Drug Safety
|
February 27, 2023
The safety and efficacy of interleukin 11 for radiation injury
Vijay K Singh, Thomas M Seed
Life Sciences in Space Research
|
November 6, 2022
Armed Forces Radiobiology Research Institute/Uniformed Services University of the Health Sciences perspective on space radiation countermeasure discovery
Vijay K Singh, Thomas M Seed
Expert Opinion on Pharmacotherapy
|
January 14, 2020
Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems
Vijay K Singh, Thomas M Seed
Expert Opinion on Drug Discovery
|
August 30, 2021
How necessary are animal models for modern drug discovery?
Vijay K Singh, Thomas M Seed
Expert Opinion on Pharmacotherapy
|
August 17, 2024
New pharmaceutical-based strategies that foster the development and promulgation of globally effective medical countermeasures for radiation exposure injuries
Vijay K Singh, Thomas M Seed
Drugs of Today (Barcelona, Spain : 1998)
|
March 11, 2022
An update on romiplostim for treatment of acute radiation syndrome
Vijay K Singh, Thomas M Seed
Expert Opinion on Drug Discovery
|
November 6, 2025
Cutting-edge animal models for radiation combined injury drug development
Vijay K Singh, Thomas M Seed
Frontiers in Pharmacology
|
May 27, 2021
Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure
Vijay K Singh, Thomas M Seed
Journal of Applied Toxicology : JAT
|
November 25, 2003
Genistein treatment protects mice from ionizing radiation injury
Michael R Landauer, Venkataraman Srinivasan, Thomas M Seed
International Journal of Radiation Biology
|
June 29, 2017
A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status
Vijay K Singh, Melissa Garcia, Thomas M Seed
Page
of 8